- Home
- Publications
- Publication Search
- Publication Details
Title
Entrectinib: First Global Approval
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-01
DOI
10.1007/s40265-019-01177-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 113OEntrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- (2019) Giles W. Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
- (2019) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
- (2018) Dazhi Liu et al. Therapeutics and Clinical Risk Management
- Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.
- (2018) Ami Vijay Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
- (2018) G D Demetri et al. ANNALS OF ONCOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia
- (2017) Kristen M. Smith et al. MOLECULAR CANCER THERAPEUTICS
- P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions
- (2017) S. Rangaraju et al. NEURO-ONCOLOGY
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
- (2016) Radhika Iyer et al. CANCER LETTERS
- Abstract 2136: Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers
- (2016) Ge Wei et al. CANCER RESEARCH
- Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers
- (2016) G. Wei et al. EUROPEAN JOURNAL OF CANCER
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- 310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101
- (2014) D. Anderson et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation